Related Experiment Video

Updated: Jul 4, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

Judith S Sebolt-Leopold1

  • 1Oncovera Therapeutics, Ann Arbor, Michigan 48103, USA. judith.leopold@comcast.net

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 19, 2008
PubMed

Insights

Targeting the extracellular signal-related kinase (ERK) pathway with MEK inhibitors shows promise in cancer drug discovery. Clinical evaluations reveal challenges in optimizing therapeutic potential due to genetic heterogeneity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The extracellular signal-related kinase (ERK) pathway is crucial in cell proliferation, survival, and metastasis, significantly impacting tumor formation and progression.
  • The RAS-RAF-MEK-ERK signaling cascade is a key target in oncology drug discovery.
  • Inhibitors targeting MAPK/ERK kinase (MEK) and RAF kinases have emerged as promising therapeutic agents.

Purpose of the Study:

  • To review the clinical evaluation of mitogen-activated protein kinase (MAPK) pathway inhibitors as anticancer agents.
  • To discuss the complexities and challenges in optimizing the therapeutic potential of these inhibitors.
  • To highlight the impact of genetic heterogeneity on treatment efficacy.

Main Methods:

  • Review of clinical trial data for MAPK pathway inhibitors.
  • Analysis of drug discovery efforts focused on MEK and RAF kinases.
  • Examination of the role of the RAS-RAF-MEK-ERK signaling cascade in human tumors.

Main Results:

  • Non-ATP-competitive MEK inhibitors effectively inhibit the ERK pathway.
  • Multiple drug candidates targeting MEK and RAF are in development.
  • Clinical evaluation of MAPK pathway inhibitors provides insights into their efficacy and limitations.

Conclusions:

  • The ERK pathway is a validated target for anticancer therapy.
  • Optimization of MAPK pathway inhibitors is complex due to patient-specific genetic heterogeneity.
  • Further research is needed to overcome resistance mechanisms and improve therapeutic outcomes.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...